|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou Y, Chen Q, Qin R, Zhang K and Li H:
MicroRNA-449a reduces cell survival and enhances cisplatin-induced
cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells.
Tumour Biol. 35:12369–12378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGuire WP: Maintenance therapy for
ovarian cancer: Of Helsinki and Hippocrates. J Clin Oncol.
27:4633–4634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kurman RJ, Visvanathan K, Roden R, Wu TC
and Shih IeM: Early detection and treatment of ovarian cancer:
Shifting from early stage to minimal volume of disease based on a
new model of carcinogenesis. Am J Obstet Gynecol. 198:351–356.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kiraz Y, Adan A, Kartal Yandim M and Baran
Y: Major apoptotic mechanisms and genes involved in apoptosis.
Tumour Biol. 37:8471–8486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaw TJ, Lacasse EC, Durkin JP and
Vanderhyden BC: Downregulation of XIAP expression in ovarian cancer
cells induces cell death in vitro and in vivo. Int J Cancer.
122:1430–1434. 2008. View Article : Google Scholar
|
|
10
|
Xie Y, Tobin LA, Camps J, Wangsa D, Yang
J, Rao M, Witasp E, Awad KS, Yoo N, Ried T, et al: MicroRNA-24
regulates XIAP to reduce the apoptosis threshold in cancer cells.
Oncogene. 32:2442–2451. 2013. View Article : Google Scholar
|
|
11
|
Frenzel A, Grespi F, Chmelewskij W and
Villunger A: Bcl2 family proteins in carcinogenesis and the
treatment of cancer. Apoptosis. 14:584–596. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Camisasca DR, Honorato J, Bernardo V, da
Silva LE, da Fonseca EC, de Faria PA, Dias FL and Lourenço SQ:
Expression of Bcl-2 family proteins and associated
clinicopathologic factors predict survival outcome in patients with
oral squamous cell carcinoma. Oral Oncol. 45:225–233. 2009.
View Article : Google Scholar
|
|
13
|
Yang T, Thakur A, Chen T, Yang L, Lei G,
Liang Y, Zhang S, Ren H and Chen M: MicroRNA-15a induces cell
apoptosis and inhibits metastasis by targeting BCL2L2 in non-small
cell lung cancer. Tumour Biol. 36:4357–4365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cory S, Huang DCS and Adams JM: The Bcl-2
family: Roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salvesen GS and Duckett CS: IAP proteins:
Blocking the road to death's door. Nat Rev Mol Cell Biol.
3:401–410. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saleem M, Qadir MI, Perveen N and Ahmad B,
Saleem U, Irshad T and Ahmad B: Inhibitors of apoptotic proteins:
New targets for anticancer therapy. Chem Biol Drug Des. 82:243–251.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
20
|
Kasof GM and Gomes BC: Livin, a novel
inhibitor of apoptosis protein family member. J Biol Chem.
276:3238–3246. 2001. View Article : Google Scholar
|
|
21
|
Adida C, Crotty PL, McGrath J, Berrebi D,
Diebold J and Altieri DC: Developmentally regulated expression of
the novel cancer anti-apoptosis gene survivin in human and mouse
differentiation. Am J Pathol. 152:43–49. 1998.PubMed/NCBI
|
|
22
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Monzó M, Rosell R, Felip E, Astudillo J,
Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A and Abad A: A
novel anti-apoptosis gene: Re-expression of survivin messenger RNA
as a prognosis marker in non-small-cell lung cancers. J Clin Oncol.
17:2100–2104. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka K, Iwamoto S, Gon G, Nohara T,
Iwamoto M and Tanigawa N: Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer
Res. 6:127–134. 2000.PubMed/NCBI
|
|
25
|
Lu CD, Altieri DC and Tanigawa N:
Expression of a novel anti-apoptosis gene, survivin, correlated
with tumor cell apoptosis and p53 accumulation in gastric
carcinomas. Cancer Res. 58:1808–1812. 1998.PubMed/NCBI
|
|
26
|
Satoh K, Kaneko K, Hirota M, Masamune A,
Satoh A and Shimosegawa T: Expression of survivin is correlated
with cancer cell apoptosis and is involved in the development of
human pancreatic duct cell tumors. Cancer. 92:271–278. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ikeguchi M, Ueta T, Yamane Y, Hirooka Y
and Kaibara N: Inducible nitric oxide synthase and survivin
messenger RNA expression in hepatocellular carcinoma. Clin Cancer
Res. 8:3131–3136. 2002.PubMed/NCBI
|
|
28
|
Han CH, Wei Q, Lu KK, Liu Z, Mills GB and
Wang LE: Polymorphisms in the survivin promoter are associated with
age of onset of ovarian cancer. Int J Clin Exp Med. 2:289–299.
2009.
|
|
29
|
Wu J, Zhao S, Zhang J, Qu X, Jiang S,
Zhong Z, Zhang F, Wong Y and Chen H: Over-expression of survivin is
a factor responsible for differential responses of ovarian cancer
cells to S-allylmercaptocysteine (SAMC). Exp Mol Pathol.
100:294–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rusca N and Monticelli S: MiR-146a in
immunity and disease. Mol Biol Int. 2011:4373012011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Navarro F and Lieberman J: Small RNAs
guide hematopoietic cell differentiation and function. J Immunol.
184:5939–5947. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bhaumik D, Scott GK, Schokrpur S, Patil
CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses
NF-kappaB activity with reduction of metastatic potential in breast
cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Halkein J, Tabruyn SP, Ricke-Hoch M,
Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert
V, Thiry M, et al: MicroRNA-146a is a therapeutic target and
biomarker for peripartum cardiomyopathy. J Clin Invest.
123:2143–2154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi G, Liu Y, Liu T, Yan W, Liu X, Wang Y,
Shi J and Jia L: Upregulated miR-29b promotes neuronal cell death
by inhibiting Bcl2L2 after ischemic brain injury. Exp Brain Res.
216:225–230. 2012. View Article : Google Scholar
|
|
39
|
Lu LF, Boldin MP, Chaudhry A, Lin LL,
Taganov KD, Hanada T, Yoshimura A, Baltimore D and Rudensky AY:
Function of miR-146a in controlling Treg cell-mediated regulation
of Th1 responses. Cell. 142:914–929. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cui Y, She K, Tian D, Zhang P and Xin X:
miR-146a inhibits proliferation and enhances chemosensitivity in
epithelial ovarian cancer via reduction of SOD2. Oncol Res.
23:275–282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sapi E, Alvero AB, Chen W, O'Malley D, Hao
XY, Dwipoyono B, Garg M, Kamsteeg M, Rutherford T and Mor G:
Resistance of ovarian carcinoma cells to docetaxel is XIAP
dependent and reversible by phenoxodiol. Oncol Res. 14:567–578.
2004.
|
|
42
|
Zhou P, Xu W, Peng X, Luo Z, Xing Q, Chen
X, Hou C, Liang W, Zhou J, Wu X, et al: Large-scale screens of
miRNA-mRNA interactions unveiled that the-3′ UTR of a gene is
targeted by multiple miRNAs. PLoS One. 8:e682042013. View Article : Google Scholar
|
|
43
|
Chen W, Zeng W, Li X, Xiong W, Zhang M,
Huang Y, Zhou L and Jiang S: MicroRNA-509-3p increases the
sensitivity of epithelial ovarian cancer cells to cisplatin-induced
apoptosis. Pharmacogenomics. 17:187–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chan WY, Cheung KK, Schorge JO, Huang LW,
Welch WR, Bell DA, Berkowitz RS and Mok SC: Bcl-2 and p53 protein
expression, apoptosis, and p53 mutation in human epithelial ovarian
cancers. Am J Pathol. 156:409–417. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qu Y, Xia P, Zhang S, Pan S and Zhao J:
Silencing XIAP suppresses osteosarcoma cell growth, and enhances
the sensitivity of osteosarcoma cells to doxorubicin and cisplatin.
Oncol Rep. 33:1177–1184. 2015.PubMed/NCBI
|
|
46
|
Chang JJ, Jeon SY, Song JY, Kim JH, Li L,
Park DH, Lee YL, Park JJ, Woo DW, Kim GJ, et al: Alteration of
X-linked inhibitors of apoptosis (XIAP) expression in rat model
with DEN-induced hepatocellular carcinogenesis. Mol Cell Toxicol.
4:278–284. 2008.
|
|
47
|
Li X, Chen W, Zeng W, Wan C, Duan S and
Jiang S: microRNA-137 promotes apoptosis in ovarian cancer cells
via the regulation of XIAP. Br J Cancer. 116:66–76. 2017.
View Article : Google Scholar
|
|
48
|
Tamm I, Kornblau SM, Segall H, Krajewski
S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, et al:
Expression and prognostic significance of IAP-family genes in human
cancers and myeloid leukemias. Clin Cancer Res. 6:1796–1803.
2000.PubMed/NCBI
|
|
49
|
Sasaki H, Sheng Y, Kotsuji F and Tsang BK:
Down-regulation of X-linked inhibitor of apoptosis protein induces
apoptosis in chemoresistant human ovarian cancer cells. Cancer Res.
60:5659–5666. 2000.PubMed/NCBI
|
|
50
|
Li J, Sasaki H, Sheng YL, Schneiderman D,
Xiao CW, Kotsuji F and Tsang BK: Apoptosis and chemoresistance in
human ovarian cancer: Is Xiap a determinant? Biol Signals Recept.
9:122–130. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gyrd-Hansen M and Meier P: IAPs: From
caspase inhibitors to modulators of NF-kappaB, inflammation and
cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pang Y, Mao H, Shen L, Zhao Z, Liu R and
Liu P: MiR-519d represses ovarian cancer cell proliferation and
enhances cisplatin-mediated cytotoxicity in vitro by targeting
XIAP. Onco Targets Ther. 7:587–597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen W, Huang L, Hao C, Zeng W, Luo X, Li
X, Zhou L, Jiang S, Chen Z and He Y: MicroRNA-155 promotes
apoptosis in SKOV3, A2780, and primary cultured ovarian cancer
cells. Tumour Biol. 37:9289–9299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu S, Zhang P, Chen Z, Liu M, Li X and
Tang H: MicroRNA-7 downregulates XIAP expression to suppress cell
growth and promote apoptosis in cervical cancer cells. FEBS Lett.
587:2247–2253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al Cancer
Genome Atlas Research Network: Integrated genomic analyses of
ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
|
